Brief intro:
- Author: Ran Zhang, Guangxue Xu, Lin Cao, Zixian Sun, Yong He, Mengtian Cui, Yuna Sun, Shentao Li, Huapeng Li, Lan Qin, Mingxu Hu, Zhengjia Yuan, Zipei Rao, Wei Ding, Zihe Rao,and Zhiyong Lou
- Journal: Nat Commun
- Doi: https://www.doi.org/10.1038/s41467-019-11668-x
- Publication Date: 2019 Aug 21
Products/Services used in the paper
Quotation shows PackGene:Huapeng Li is one of the authors
Research Field:adeno-associated viruses with their cellular receptor AAVR
AAV Serotype:AAV1; AAV5
Abstract
Adeno-associated virus (AAV) receptor (AAVR) is an essential receptor for the entry of multiple AAV serotypes with divergent rules; however, the mechanism remains unclear. Here, we determine the structures of the AAV1-AAVR and AAV5-AAVR complexes, revealing the molecular details by which PKD1 recognizes AAV5 and PKD2 is solely engaged with AAV1. PKD2 lies on the plateau region of the AAV1 capsid. However, the AAV5-AAVR interface is strikingly different, in which PKD1 is bound at the opposite side of the spike of the AAV5 capsid than the PKD2-interacting region of AAV1. Residues in strands F/G and the CD loop of PKD1 interact directly with AAV5, whereas residues in strands B/C/E and the BC loop of PKD2 make contact with AAV1. These findings further the understanding of the distinct mechanisms by which AAVR recognizes various AAV serotypes and provide an example of a single receptor engaging multiple viral serotypes with divergent rules.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
